Arcus Biosciences Gross Margin 2017-2023 | RCUS

Current and historical gross margin for Arcus Biosciences (RCUS) over the last 10 years. The current gross profit margin for Arcus Biosciences as of March 31, 2023 is %.
Arcus Biosciences Gross Margin Historical Data
Date TTM Revenue TTM Gross Profit Gross Margin
2023-03-31 $0.12B $0.12B 100.00%
2022-12-31 $0.11B $0.11B 100.00%
2022-09-30 $0.43B $0.43B 100.00%
2022-06-30 $0.41B $0.41B 100.00%
2022-03-31 $0.39B $0.39B 100.00%
2021-12-31 $0.38B $0.38B 100.00%
2021-09-30 $0.04B $0.04B 100.00%
2021-06-30 $0.09B $0.09B 100.00%
2021-03-31 $0.09B $0.09B 100.00%
2020-12-31 $0.08B $0.08B 100.00%
2020-09-30 $0.08B $0.08B 100.00%
2020-06-30 $0.02B $0.02B 100.00%
2020-03-31 $0.02B $0.02B 100.00%
2019-12-31 $0.02B $0.02B 100.00%
2019-09-30 $0.01B $0.01B 100.00%
2019-06-30 $0.01B $0.01B 100.00%
2019-03-31 $0.01B $0.01B 100.00%
2018-12-31 $0.01B $0.01B 100.00%
2018-09-30 $0.01B $0.01B 100.00%
2018-06-30 $0.00B $0.00B 100.00%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.536B $0.112B
Arcus Biosciences is a biopharmaceutical company. It focused on creating innovative cancer immunotherapies. The company's product portfolio includes AB928, AB122, AB154 and AB680. AB928 which is in its final phase is a potent and selective dual antagonist of the adenosine receptors. AB122 which is in its Phase1 is a monoclonal antibody which potently and selectively blocks a protein called PD-1. AB154 is a monoclonal antibody which potently and selectively blocks a novel immune checkpoint called TIGIT. AB680, which is in its Phase1 is a potent and selective inhibitor of CD73, the enzyme responsible for the extracellular production of adenosine within the tumor micro-environment. Arcus Biosciences is based in Hayward, CA.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $137.942B 8.43
GSK (GSK) United Kingdom $69.839B 9.75
Bio-Rad Laboratories (BIO.B) United States $10.988B 29.38
QIAGEN (QGEN) Netherlands $10.584B 22.35
Ginkgo Bioworks Holdings (DNA) United States $3.379B 0.00
Biohaven (BHVN) United States $1.482B 0.00
Emergent Biosolutions (EBS) United States $0.416B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.191B 0.00
Enzo Biochem (ENZ) United States $0.110B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00